cabozantinib

• 

Triple combination for previously untreated advanced non-clear cell kidney cancer

By Sharon Deveson Kell|2023-06-08T08:24:50+00:007 Jun 2023|Drug treatments|

The COSMIC-313 study previously showed improved survival when combining cabozantinib [...]

Read More

Comments Off on Triple combination for previously untreated advanced non-clear cell kidney cancer

• 

Cabozantinib plus atezolizumab in non-clear cell kidney cancer

By Sharon Deveson Kell|2023-05-18T08:11:24+00:0018 May 2023|Drug treatments|

The results from an extended follow-up of the phase 1b [...]

Read More

Comments Off on Cabozantinib plus atezolizumab in non-clear cell kidney cancer

• 

Triple combination improves survival in patients with advanced kidney cancer

By Sharon Deveson Kell|2023-05-15T08:11:29+00:0015 May 2023|Drug treatments|

Results from the phase 3 COSMIC-313 trial showed that adding [...]

Read More

Comments Off on Triple combination improves survival in patients with advanced kidney cancer

• 

Belzutifan plus cabozantinib combination shows promising results in kidney cancer

By Sharon Deveson Kell|2023-04-11T09:04:23+00:0011 Apr 2023|Drug treatments|

Kidney cancers often have mutations in a gene called the [...]

Read More

Comments Off on Belzutifan plus cabozantinib combination shows promising results in kidney cancer

• 

ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer

By Sharon Deveson Kell|2023-03-07T14:41:49+00:007 Mar 2023|Drug treatments|

At the American Society of  Clinical Oncology Genitourinary Cancers Conference [...]

Read More

Comments Off on ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer

• 

ASCO GU 2023: A triple combination for previously untreated kidney cancer patients

By Sharon Deveson Kell|2023-03-07T14:33:29+00:007 Mar 2023|Drug treatments|

At the American Society of  Clinical Oncology Genitourinary Cancers Conference [...]

Read More

Comments Off on ASCO GU 2023: A triple combination for previously untreated kidney cancer patients

• 

ASCO GU 2023: Further information from the cabozantinib plus nivolumab study

By Sharon Deveson Kell|2023-02-23T14:39:48+00:0023 Feb 2023|Drug treatments|

At the American Society of  Clinical Oncology Genitourinary Cancers Conference [...]

Read More

Comments Off on ASCO GU 2023: Further information from the cabozantinib plus nivolumab study

• 

Telaglenastat plus cabozantinib in patients with metastatic kidney cancer

By Sharon Deveson Kell|2022-09-23T07:17:06+00:0023 Sep 2022|Drug treatments|

Cell metabolism in kidney cancer tumours is disrupted, and tumour [...]

Read More

Comments Off on Telaglenastat plus cabozantinib in patients with metastatic kidney cancer

• 

ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease

By Sharon Deveson Kell|2022-09-14T08:26:50+00:009 Sep 2022|Drug treatments|

The results of COSMIC-131 were presented at the European Society [...]

Read More

Comments Off on ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease

• 

Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinoma

By Sharon Deveson Kell|2022-08-23T14:44:26+00:0023 Aug 2022|Drug treatments|

MiT family translocation renal cell carcinoma is a rare and [...]

Read More

Comments Off on Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinoma